Advertisement

Pharmacy

A 79-year-old man with recurrent oropharyngeal cancer has developed the first documented case of severe drug-induced interstitial lung disease following photoimmunotherapy with cetuximab-sarotalocan sodium, according to a July 5 case report published in Science Direct.  Here are four notes: 

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least four prior therapies, the agency said July 2.  The approval is based on…

Children’s National Hospital, based in Washington, D.C., earned accreditation for its specialty pharmacy services from URAC, an independent accreditor that sets national standards for quality and patient safety.  This marks the second URAC accreditation for Children’s National, which previously received…

Here are six new drug shortages and discontinuations, according to drug supply databases from the FDA. 

Advertisement

The battle over pharmacy benefit manager regulation is intensifying across the U.S. With the Supreme Court declining to revisit a key PBM case and Illinois signing sweeping new restrictions into law, PBM oversight remains a complex and evolving issue.  Here…

Health systems are rethinking how they structure and support their pharmacy teams, and the results are showing. Across the country, pharmacy leaders are implementing workforce changes to improve care delivery and drive greater operational efficiency.  Here are responses from three…

As GLP-1 medications including Wegovy, Ozempic, Mounjaro and Zepbound reshape diabetes and weight loss care, recent developments such as new partnerships, safety questions and challenges in patient persistence show the landscape is quickly changing.  Here are five recent GLP-1 developments: …

The American Hospital Association and three other healthcare organizations have filed an amicus brief defending Tennessee’s 340B contract pharmacy law, which is facing a challenge from the pharmaceutical industry.  Here are three notes: 

Standard first-line drug therapies for the treatment of bone density disorders have been linked to higher risk of experiencing a cardiovascular event, according to a study published June 26 in Epic Research. Here are five notes on the study: Read…

Advertisement